NICE’s final draft guidance (published Friday 3 May 2024), recommends voxelotor (also called Oxbryta and made by Pfizer) with or without another treatment for SCD called hydroxycarbamide.
Suggested remit: To appraise the clinical and cost effectiveness of hydromethylthionine mesylate within its marketing authorisation for treating mild cognitive impairment or mild or moderate dementia ...
The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...
The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...
Chapter 2 of Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) – A new deal for patients, taxpayers and industry states that for those drugs with a draft ...
The heart needs a constant supply of blood. In coronary heart disease, this blood supply gets interrupted or blocked by a build-up of fatty substances in the coronary arteries. Drug eluting stents are ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...
Pembrolizumab (Keytruda, MSD) is indicated for 'the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous ...
Pembrolizumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had at least 2 previous treatments and cannot have an ...
The appraisal committee has prepared final draft guidance (FDG) on pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma and submitted it to NICE. The FDG has been sent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results